<DOC>
	<DOCNO>NCT00768963</DOCNO>
	<brief_summary>The primary purpose trial evaluate safety tolerability ranibizumab give via subconjunctival injection patient undergo pterygium surgery .</brief_summary>
	<brief_title>Ranibizumab Inhibition Neovascularization Pterygia</brief_title>
	<detailed_description>As secondary objective , study also aim establish tissue concentration ranibizumab deliver via subconjunctival injection patient undergo pterygium excision determine effect ranibizumab conjunctival healing , corneal epithelial healing , wound dehiscence .</detailed_description>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Pterygium</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Subjects eligible follow criterion meet : Ability provide write informed consent comply study assessment full duration study Age &gt; 18 year Patient relate consideration : All patient gender consider enrollment . Disease related consideration : Patients pterygia consider enrollment pterygium meet standard pterygium excision criterion include encroachment visual axis severe induced astigmatism foreign body sensation unresponsive medical therapy . Subjects meet follow criterion exclude study : Pregnancy ( positive pregnancy test ) Women seek become pregnant Lactating woman Prior enrollment study Prior glaucoma surgery region pterygium Any condition investigator believe would pose significant hazard subject investigational therapy initiate Participation another simultaneous medical investigation trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>ranibizumab</keyword>
	<keyword>pterygium</keyword>
</DOC>